The Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Guidelines are a collection of consensus statements developed by experts to help oncologists determine when and how to best use immunotherapy to treat their patients. The guidelines are developed using a systematic process to ensure the recommendations are unbiased, relevant, and facilitate clinical decision-making. The guidelines will be evaluated and updated on an ongoing basis.
Prior to publication of each guideline, a Member Comment period is launched to allow SITC members to review a draft copy of the guideline and provide feedback, with the goal of further improving the draft. Click here to learn more about the Member Comment period.
In response to the ever-growing demand for expert guidance on the optimal use of immunotherapy treatments, our Cancer Immunotherapy Guidelines committees have developed consensus statements for cutaneous melanoma, genitourinary malignancies (renal, prostate and bladder carcinoma), hematologic malignancies (multiple myeloma, lymphoma and acute leukemia) and non-small cell lung cancer.
Work on new guidelines for head and neck cancers is currently underway. These disease-specific Cancer Immunotherapy Guidelines offer a vital resource for the practicing oncology community.
Join leading experts in the field of non-small cell lung cancer during an upcoming free webinar focused on the recently published SITC Cancer Immunotherapy Guidelines manuscript.
Join experts in the field to discuss immunotherapy treatment guidelines for non-small cell lung cancer. Hear about The Society for Immunotherapy of Cancer’s recently published consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) during a FREE webinar on Sept. 13 at 1 p.m. EDT. CME, CNE and CPE-credits are available for webinar attendees.
Led by experts in the field:
Register now to participate in this informal webinar with Drs. Brahmer, Forde, Gettinger and Herbst to learn about the most recent immunotherapy treatment standards for non-small cell lung cancer. Hear about consensus recommendations on scheduling of available immunotherapies across disease settings, guidelines concerning biomarker utilization and discussion on how best to manage immune-related adverse events.
Download this promotional flyer to share to your colleagues!
Published May 30, 2018 in Journal for ImmunoTherapy of Cancer (JITC) as "An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0."
Published Nov. 15, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma."
Published Dec. 20, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma."
Published Aug. 15, 2017 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma."
Published Dec. 20, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia."
Published July 17, 2018 in Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)"
Key points from SITC's Cancer Immunotherapy Guidelines have been distilled into Pocket Guides. These condensed, easily accessible versions of the full Cancer Immunotherapy Guidelines are a quick-reference tool available in both digital and print.
Download SITC's Cancer Immunotherapy Pocket Guides on any desktop or mobile device free today.*
*Available only through the Guideline Central App.
ORDER Digital/Print Guides
SITC follows the 2011 Institute of Medicine’s “Standards for Developing Trustworthy Clinical Practice Guidelines” to assure a fair, transparent and balanced process for creating each consensus statement; therefore, each Cancer Immunotherapy Guidelines subcommittee comprises a comprehensive mix of academic physicians and researchers, nurses, patients, and patient advocates invited from institutions across the United States.
Each expert committee addresses knowledge gaps in our understanding of immunotherapy treatments for their disease specialty, and develops evidence-based recommendations by evaluating the published literature and providing their opinions on key issues, documenting alternative opinions when they occur.
Memorial Sloan Kettering Cancer Center invites you to attend the 2018 Annual Cancer Treatment-Related Adverse Events Symposium on Friday-Saturday, October 26-27 , at Zuckerman Research Center in New York. Systemic anticancer therapies including ...
We are currently organizing the 8 th InterAmerican Oncology Conference, "Current Status and Future of Anti-Cancer Therapies" will take place on October 17 th and 18 th , 2019 in Buenos Aires, Argentina.
Dres. Alex Adjei (Mayo Clinic, USA), Román ...
Usage of CRISPR/Cris9, an RNA guided DNA gene editing technology has powerful manipulative abilities. It has a special place in genetic engineering in its development. There is current development of this technology for therapeutic applications, particularly ...
Hi all- Fight Colorectal Cancer (CRC) will be hosting a webinar next Wednesday August 8th at 1:30p EST around biomarkers such as BRAF and HER2, as well as sidedness and what these mean for tailoring treatment for colorectal cancer patients. Be sure ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com